Table 1.
Clinical data of patients and microbiological and molecular data of CTX-M-15-producing isolates
| Patient | Sexa | Age (yr) | Diagnosis | Underlying disease(s)b | ATB last 3 moc | MIC (μg/ml)f |
Virulence factor genes | Other bla genes detected | Presence ofe: |
Phylogenetic group | MLSTd |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CTX | CAZ | FEP | TZP | ETP | MEM | CIP | AMK | qnr | aac(6′)-Ib-cr | CC | ST | |||||||||
| 1 | F | 85 | Cystitis | R-UTI, UI | NIT, CIP | >32 | 8 | 8 | ≤8/4 | ≤0.5 | ≤0.12 | >8 | ≤8 | PAI, iutA, traT | None | − | + | A | 10 | 617 |
| 2 | F | 80 | Cystitis | R-UTI | No | >32 | 32 | 16 | ≤8/4 | ≤0.5 | ≤0.12 | >8 | ≤8 | PAI, iutA, traT | None | − | + | A | 10 | 617 |
| 3 | M | 30 | Peritonitis | Ulcerative colitis | No | >32 | 8 | 8 | ≤8/4 | ≤0.5 | ≤0.12 | >8 | ≤8 | fimH, iutA, traT | None | − | + | A | 10 | 44 |
| 4 | F | 80 | Cystitis | UI, HTN | CIP | 16 | ≤2 | 2 | ≤8/4 | ≤0.5 | ≤0.12 | 8 | 16 | fimH, iutA, traT | None | − | + | A | 10 | 44 |
| 5 | F | 69 | Cystitis | R-UTI | NIT | >32 | 16 | 32 | 16/4 | ≤0.5 | ≤0.12 | >8 | ≤8 | fimH, fyuA | blaTEM-1 | − | + | D | 405 | 405 |
| 6 | F | 75 | Cystitis | R-UTI, UI | NIT | >32 | 32 | 16 | ≤8/4 | ≤0.5 | ≤0.12 | >8 | ≤8 | fimH, fyuA | blaTEM-1 | − | + | D | 405 | 405 |
| 7 | F | 88 | Pyelonephritis | CRF, CHF, DM2 | No | 16 | 8 | 8 | ≤8/4 | ≤0.5 | ≤0.12 | >8 | ≤8 | PAI, fimH, fyuA, iutA, traT | None | − | + | D | 405 | 405 |
| 8 | F | 18 | Cystitis | None | No | >32 | 16 | 16 | ≤8/4 | ≤0.5 | ≤0.12 | >8 | ≤8 | ompT, PAI, fyuA, traT | blaTEM-1 | − | − | D | None | 2043 |
| 9 | F | 81 | Pyelonephritis | Alzheimer's disease | No | >32 | 32 | 32 | 16/4 | ≤0.5 | ≤0.12 | >8 | 16 | ompT, PAI, fyuA | blaTEM-1 | − | + | D | 648 | 648 |
| 10 | M | 80 | Cystitis | R-UTI, COPD | No | >32 | 32 | 32 | 32/4 | 2 | 0.25 | >8 | ≤8 | PAI, ompT, fimH, fyuA, traT | None | − | + | D | 648 | 648 |
| 11 | M | 2 | Cystitis | None | No | >32 | >32 | 64 | 32/4 | ≤0.5 | ≤0.12 | 8 | 32 | PAI, fimH, iutA, traT | None | − | + | D | None | 1722 |
| 12 | F | 2 | Cystitis | None | No | >32 | 8 | 16 | ≥128/4 | ≤0.5 | ≤0.12 | >8 | ≤8 | usp, ompT, PAI, fimH, fyuA, iutA, traT | blaTEM-1 | − | + | B2 | None | 131 |
| 13 | F | 69 | Cystitis | R-UTI, UI, HTN | CIP | >32 | >32 | 32 | 32/4 | ≤0.5 | ≤0.12 | >8 | ≤8 | usp, ompT, PAI, fimH, fyuA, iutA, traT | blaTEM-1 | − | + | B2 | None | 131 |
| 14 | F | 64 | Cystitis | UI, DM2, HTN | No | 32 | 32 | 2 | ≤8/4 | ≤0.5 | ≤0.12 | >8 | ≤8 | usp, ompT, PAI, papC, fimH, fyuA, iutA | blaTEM-1 | − | + | B2 | None | 2042 |
a
F, female; M, male.
b
R-UTI, repetitive urinary tract infection; UI, urinary incontinence; HTN, arterial hypertension; CRF, chronic renal failure, CHF, congestive heart failure; DM2, diabetes mellitus 2; COPD, chronic obstructive pulmonary disease.
c
ATB, antibiotic; NIT, nitrofurantoin; CIP, ciprofloxacine.
d
ST, sequence type; CC, clonal complex.
e
+, positive; −, negative.
f
CTX, cefotaxime; CAZ, ceftazidime; FEP, cefepime; TZP, piperacillin-tazobactam; ETP, ertapenem; MEM, meropenem; AMK, amikacin.